_edited.png)
From Litigator to HHS Insider: Inside Matt Zorn’s Federal Psychedelic Agenda
Fast Facts
Who / Where: Matt Zorn, Deputy General Counsel at the U.S. Department of Health and Human Services (HHS), addressing the Psychedelic Healthcare Forum in New York.
What changed: The former drug policy litigator, known for challenging federal agencies on cannabis rescheduling and psilocybin access, has now pivoted to directing federal psychedelic policy within HHS.
Effective / Key date: Zorn started his role at HHS in May 2025; President Trump signed a psychedelics-focused executive order in April 2026.
Status: HHS is actively pursuing federal initiatives under the executive order, while scheduling challenges concerning five psychedelic tryptamines remain unresolved.
DMV impact: Changes in federal drug administration suggest sweeping reviews that could redefine how scheduling, research access, and therapeutic practices are managed across Virginia, Maryland, and Washington, D.C.
The bottom line: In October 2026, Deputy General Counsel Matt Zorn confirmed that HHS is diligently executing the April 2026 presidential executive order aimed at exploring psychedelic solutions to the national mental health crisis—a significant departure from previous administrative resistance to innovative drug therapies.
Federal drug scheduling has historically functioned as a fortified barrier, rarely bending to outside pressures or emerging scientific evidence. For years, advocacy for therapeutic use has contended with a perplexing blend of state-level reforms and stringent federal prohibitions.
However, this landscape dramatically shifted when Matt Zorn moved from being a formidable legal challenger against the government to a key player within HHS. Speaking at the Psychedelic Healthcare Forum hosted by Psychedelic Alpha, Zorn discussed his new role and the ongoing efforts in administrative access and scheduling reform.
Who Is Matt Zorn and What Is His Role at HHS?
Matt Zorn serves as the Deputy General Counsel for the U.S. Department of Health and Human Services (HHS), making him the focal point for federal psychedelic policy. Prior to his appointment in May 2025, Zorn established a national reputation by legally jousting with both the Drug Enforcement Administration (DEA) and HHS, addressing regulatory delays and barriers surrounding controlled substances.
His private practice and contributions to On Drugs with Shane Pennington notably included advocating for psilocybin access through Right to Try legislation. Zorn also spearheaded petitions for cannabis rescheduling and legally challenged the DEA's attempt to classify five synthetic psychedelic tryptamines as Schedule I substances.
In a twist of fate, Zorn revealed that his appointment to HHS was influenced by his history of effectively challenging federal regulators in court. Instead of viewing him as an adversary, agency leadership enlisted a critique-oriented legal expert to reassess conventional institutional assumptions from within.
How Does Federal Drug Administration Impact Local Regulatory Enforcement?
As HHS modifies federal drug policy, the reverberations significantly affect state regulatory frameworks, medical cannabis programs, and commerce regulations. Virginia, Maryland, and D.C. regulators must continually assess how these federal updates align with state-sanctioned distribution, cultivation, and delivery procedures.
In established markets, licensed operators keep a keen eye on federal classifications, as scheduling impacts taxation, research pathways, and transportation rules. With more certainty in regulations, commercial courier networks and local retail operations can navigate compliance across varying jurisdictions. Openness from federal agencies to rethink scheduling conventions—like permitting therapeutic regulation while restricting a compound elsewhere—paves the way for broader regulatory modernization.
Milestones in the Shift Toward Federal Psychedelic Administration
The evolution of oversight for psychedelics at the federal level has swiftly transitioned from courtroom battles to significant agency policymaking. The following timeline highlights key events that have brought this legal reform into the executive branch:
Date | Event | What It Means |
|---|---|---|
December 2024 | Pre-Appointment Forum Analysis | Zorn recognized political instability as an opportunity to challenge federal drug policy. |
May 2025 | HHS Appointment | Zorn became Deputy General Counsel, taking the lead on psychedelics. |
April 2026 | Psychedelics Executive Order | President Trump issued an executive directive focusing on psychedelic therapeutic initiatives. |
October 2026 | Psychedelic Healthcare Forum | Zorn publicly detailed HHS’s internal efforts, highlighting bipartisan support for clinical access. |
The April 2026 Executive Order and Questioning Bureaucratic Assumptions
At the heart of HHS's evolving policy agenda is the psychedelic-focused executive order signed in April 2026. Zorn played a pivotal role in shaping this initiative, aimed at dismantling bureaucratic inertia and reallocating federal health resources towards advanced mental health solutions. Despite the unpredictable political landscape, Zorn described the regulatory processes at HHS as methodical, measured, and unexpectedly bipartisan.
Historically, federal drug reform stalled due to deeply ingrained administrative conventions, not statutory roadblocks. In prior legal analyses, Zorn questioned the legitimacy of bifurcated scheduling—where a pharmaceutical formulation containing a restricted compound receives a lower schedule while the compound itself remains a Schedule I substance. Although his current role limits his ability to discuss pending petitions, his previous work illustrates that many longstanding barriers are entrenched institutional habits rather than hard laws.
What This Means for Virginia Residents
For Virginians and cannabis users across the Commonwealth, the evolution of federal scheduling policy provides insightful context on how regional access laws evolve. Virginia has implemented marijuana laws that permit adult possession and decriminalization, yet the state has faced prolonged debates regarding the launch of a regulated retail market. While Virginians can cultivate limited amounts at home, commercial access primarily hinges on the state-sanctioned medical program.
Federal actions spearheaded by HHS highlight a critical principle relevant to Virginia's cannabis landscape: moving from administrative bans to regulated access necessitates overcoming inertia in existing regulatory mechanisms. As federal health officials explore pathways for clinical access, Virginia consumers and advocates are keenly observing to see if these actions will encourage states to foster robust regulatory frameworks instead of relying on outdated federal prohibitions.
Moreover, Virginia operators handling complex transport, processing, and delivery regulations look to federal policy cues to better understand how future medical and therapeutic supply chains will be regulated. While the state has yet to legalize a broad adult-use dispensary market, shifts in federal policy could expedite conversations about developing structured distribution models, patient rights, and legal protections for alternative therapies.
How This Compares to Other States
The dialogue ongoing within HHS resonates with distinct regulatory experiments materializing nationwide. States such as Oregon and Colorado have adopted voter-backed measures establishing supervised, state-regulated access masks for natural psychedelics, functioning independently of the federal healthcare framework. By contrast, East Coast jurisdictions often employ a more cautious, clinically directed approach heavily dependent on federal endorsement or medical institutional support.
In Maryland, lawmakers have set up task forces to evaluate therapeutic psychedelic models, aligning state research agendas with prospective federal rescheduling. Meanwhile, Washington, D.C. passed Initiative 81 in 2020, pushing entheogenic plants and fungi to the lowest law enforcement priority for the Metropolitan Police. This starkly illustrates that, while western states have crafted parallel state-level licensing frameworks, mid-Atlantic jurisdictions are still intricately connected to how federal agencies like HHS and the DEA regulate these substances.
Bud Lords Take: Inside Reform and the Limits of Bureaucracy
Here's our takeaway: appointing a savvy, reform-minded litigator like Matt Zorn to HHS is a significant win for advancing pragmatic drug policy. For years, federal drug enforcement operated within an echo chamber, reinforcing Schedule I classifications long after medical benefits were established in peer-reviewed studies. With Zorn's legal acumen and his understanding of the Administrative Procedure Act, federal health officials face heightened expectations for expediting reforms rather than defaulting to standard bureaucratic delays.
Nonetheless, as Zorn himself observed, government bureaucracy often progresses slower from within than it appears externally. The true litmus test of the April 2026 executive order will not rest in lofty speeches or health forum appearances; it will hinge on concrete administrative rulings, recognized petitions, and clear regulatory pathways that ensure safe, accessible treatment options for patients in need.
Timeline and Next Steps
Looking ahead, specific key initiatives and active dockets will challenge the impact of HHS's current policy stance:
Tryptamine Scheduling Proceedings: A legal challenge against the DEA’s proposed Schedule I classification for five synthetic psychedelic tryptamines is now back in consideration, marking a vital test case for federal scheduling protocols.
Executive Order Guidance: HHS and associated agencies are anticipated to issue guidance clarifying how federal research entities can explore these compounds without facing regulatory bottlenecks.
Right to Try Enforcement: Determinations on whether terminally ill patients may access experimental therapies under federal Right to Try statutes will delineate the lines between patient rights and DEA scheduling control.
Who is Matt Zorn?
Matt Zorn is an attorney serving as the Deputy General Counsel at the U.S. Department of Health and Human Services (HHS). Before joining the government in May 2025, he was known for litigating against federal entities like the DEA and HHS to promote cannabis and psychedelic policy reform.
What was the focus of the April 2026 psychedelics executive order?
In April 2026, President Trump signed an executive order aimed at reevaluating and modernizing federal policies on psychedelic therapies. The order instructs agencies to challenge established assumptions and investigate innovative interventions for the national mental health crisis.
What does Right to Try mean in the context of psychedelic therapies?
Right to Try laws allow patients with life-threatening conditions to access eligible investigational drugs that have completed preliminary clinical testing but haven't received full FDA approval. Prior to his HHS position, Zorn fought to expand these protections to therapeutic psilocybin access.
Does federal rescheduling legalize cannabis or psychedelics nationwide?
No. Federal rescheduling of a substance changes its regulatory thresholds, research protocols, and tax rules, but it doesn't automatically establish retail markets or override state-specific criminal laws.
How does this federal discussion affect Virginia's cannabis landscape?
While Virginia has its own decriminalization and medical cannabis laws, changes at the federal level affect research capabilities, national medical standards, and future regulatory expectations for retail compliance across the mid-Atlantic.
As the federal government moves forward with its ongoing directives, staying informed about administrative changes is essential for understanding the evolving landscape of drug policy. Follow us at Bud Lords for the latest updates and insights on how market regulations, consumer rights, and federal decisions are shaping the future of legal access across the DMV.
Have a cannabis story, local update, or strain you want our newsroom to cover? Request a story →
Written by Massachusetts Cannabis AI
Bud Lords AI Cannabis News Writer
East Coast cannabis market expert focusing on Massachusetts' evolving industry, Boston-area businesses, New England regulations, and social equity programs. Covers Cape Cod to Berkshires market dynamics.
Expertise: massachusetts · boston · new-england · social-equity · east-coast · berkshires
This AI-assisted article was created using the named Bud Lords newsroom personality and reviewed under Bud Lords editorial standards.
Comments